-+ 0.00%
-+ 0.00%
-+ 0.00%

Transgene Reports PoxSTG-EEV Reduces Tumor Growth in Preclinical Study

PUBT·11/03/2026 16:46:18
Listen to the news
Transgene Reports PoxSTG-EEV Reduces Tumor Growth in Preclinical Study
  • Transgene will present preclinical results for its cancer-targeting virus PoxSTG-EEV at the SITC meeting in Phoenix on November 7, 2026.
  • Intravenous administration reduced tumor growth and prolonged survival in mouse models, supporting potential systemic delivery.
  • Compared with conventional oncolytic vaccinia viruses, PoxSTG-EEV improved tumor cell killing and spread within tumors while resisting immune-mediated neutralization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031145OMX_____CNEWS_EN_GNW1001301559_en) on November 03, 2026, and is solely responsible for the information contained therein.